A Comparison of The Effects of Clobetasol 0.05% and Photodynamic Therapy Using Aminolevulinic Acid With Red Light in the Treatment of Severe Nail Psoriasis

Introduction: The treatment of nail psoriasis is often difficult and unsatisfactory due to therapy resistance. This study aimed to compare the efficacy of clobetasol 0.05% ointment and photodynamic therapy (PDT) using aminolevulinic acid (ALA) and red light in the treatment of severe nail psoriasis. Methods: This open-trial study included 69 nails of 8 patients with severe nail psoriasis. Thirty-four nails were treated with clobetasol 0.05% ointment and 35 nails were treated with ALA-PDT. ALAPDT treatment was performed every 3 weeks for 5 cycles; the nails were treated with clobetasol under occlusion every day during the study. All the patients were followed up after 24 weeks. The severity of nail involvement was measured by the Nail Psoriasis Severity Index (NAPSI) scores at the baseline and during the treatment. Results: There were no significant differences in the NAPSI scores between the treatment groups in the baseline and weeks 3, 6 and 9 (all P>0.05), although significant differences were found in weeks 12, 15 and 24 (follow-up) (P<0.001). A significant time-effect improvement was found in all the nailmatrix, nail-bed and total NAPSI scores in both treatment groups (all P<0.001). The patients did not report intense pain and discomfort during irradiation. Conclusion: Clobetasol 0.05% ointment seems to be effective in treating nail psoriasis after a treatment period of 15 weeks. However, the efficacy of ALA-PDT at a 24-week follow-up was greater than that of clobetasol.

Download Full-text

Photodynamic Therapy for the Treatment of Infected Leg Ulcers—A Pilot Study

Antibiotics ◽

10.3390/antibiotics10050506 ◽

2021 ◽

Vol 10 (5) ◽

pp. 506

Author(s):

Magdalena Krupka ◽

Andrzej Bożek ◽

Dorota Bartusik-Aebisher ◽

Grzegorz Cieślar ◽

Aleksandra Kawczyk-Krupka

Keyword(s):

Photodynamic Therapy ◽

Rating Scale ◽

Aminolevulinic Acid ◽

Red Light ◽

Numeric Rating Scale ◽

Laser Source ◽

Leg Ulcers ◽

Octenidine Dihydrochloride

Chronic and infected leg ulcers (LUs) are painful, debilitating, resistant to antibiotics, and immensely reduce a patient’s quality of life. The purpose of our study was to demonstrate the efficacy of photodynamic therapy (PDT) for the treatment of infected chronic LUs. Patients were randomized into two experimental groups: the first group received 5-aminolevulinic acid photodynamic therapy (ALA-PDT) (10 patients), and the second group of 10 patients received local octenidine dihydrochloride (Octenilin gel) exposed to a placebo light source with an inserted filter that mimiced red light. In the PDT group, we used 20% ALA topically applied for 4 hrs and irradiation from a Diomed laser source with a wavelength of 630 nm at a fluency of 80 J/cm2. ALA-PDT was performed 10 times during a 14-day hospitalization in 10 patients of both sexes aged 40–85 years with chronic leg ulcers. Treatments were carried out at 3-week intervals for 3–5 cycles. At 8-month follow-up with the PDT group, complete remission (CR) was obtained in four patients (40%), partial response (>50% reduction in ulcer diameter) in four patients (40%), and no response in two patients (20%) who additionally developed deterioration of the local condition with swelling, erythema, and inflammation. To assess the degree of pain during the trials, we used a numeric rating scale (NRS). From the preliminary results obtained, we concluded that PDT can be used to treat leg ulcers as a minimally invasive and effective method with no serious side effects, although further studies on a larger group of patients with LUs are warranted.

Download Full-text

Follow-up results of a randomized, double-blind, phase III, multi-center study to evaluate the safety and efficacy of BF-200 ALA versus placebo in field-directed treatment of mild to moderate AK with photodynamic therapy when using narrowband red light

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.3.supp.49 ◽

2019 ◽

Vol 3 ◽

pp. S49

Author(s):

U Reinhold ◽

T Dirschka ◽

R Ostendorf ◽

R Aschoff ◽

C Berking ◽

...

Keyword(s):

Photodynamic Therapy ◽

Red Light ◽

Phase Iii ◽

Double Blind ◽

Safety And Efficacy ◽

Multi Center Study ◽

Center Study

Abstract not available.

Download Full-text

Safety of Large Field (>20cm2) Photodynamic Therapy Using 10% Aminolevulinic Acid Hydrochloride Nanoemulsion Gel Comparing Blue to Red Light Illumination

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.3.supp.46 ◽

2019 ◽

Vol 3 ◽

pp. S46

Author(s):

Angela Yen Moore ◽

Stephen Moore

Keyword(s):

Photodynamic Therapy ◽

Aminolevulinic Acid ◽

Red Light ◽

Large Field ◽

Light Illumination ◽

Nanoemulsion Gel ◽

Acid Hydrochloride

Abstract not available.

Download Full-text

Faculty Opinions recommendation of Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718006556.793483944 ◽

2013 ◽

Author(s):

Murad Alam ◽

Kira Minkis

Keyword(s):

Randomized Controlled Trial ◽

Photodynamic Therapy ◽

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Aminolevulinic Acid ◽

Controlled Trial ◽

Surgical Excision ◽

Randomized Controlled

Download Full-text

Faculty Opinions recommendation of Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718006556.793477614 ◽

2013 ◽

Author(s):

April W Armstrong

Keyword(s):

Randomized Controlled Trial ◽

Photodynamic Therapy ◽

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Aminolevulinic Acid ◽

Controlled Trial ◽

Surgical Excision ◽

Randomized Controlled

Download Full-text

Subclinical Cardiac Organ Damage in Patients with Moderate to Severe Psoriasis

Journal of Clinical Medicine ◽

10.3390/jcm10112440 ◽

2021 ◽

Vol 10 (11) ◽

pp. 2440

Author(s):

Anja Linde ◽

Eva Gerdts ◽

Kåre Steinar Tveit ◽

Ester Kringeland ◽

Helga Midtbø

Keyword(s):

Body Mass Index ◽

Body Mass ◽

Treatment Initiation ◽

Severity Index ◽

Organ Damage ◽

Left Ventricular ◽

Infliximab Treatment ◽

Increased Risk ◽

Psoriasis Severity

We explored the association between subclinical cardiac organ damage (OD) with comorbidities and psoriasis severity in 53 psoriasis patients on infliximab treatment (age 47 ± 15 years, 30% women) and 99 controls without psoriasis (age 47 ± 11 years, 28% women). Cardiac OD was assessed by echocardiography as the presence of increased left ventricular (LV) relative wall thickness (RWT), LV hypertrophy or dilated left atrium. Psoriasis severity was graded using the psoriasis area and severity index (PASI). The prevalence of hypertension was 66% in psoriasis vs. 61% in controls (p = 0.54) and cardiac OD seen in 51 and 73%, respectively (p = 0.007). Psoriasis was associated with a lower prevalence of cardiac OD (odds ratio (OR) 0.32, 95% confidence interval (CI) 0.13–0.77, p = 0.01) independent of age, sex, smoking, body mass index, and hypertension. Among psoriasis patients, hypertension was associated with increased risk of subclinical cardiac OD (OR 6.88, 95% CI 1.32–35.98, p = 0.02) independent of age, sex, and body mass index. PASI at treatment initiation was associated with a higher RWT at follow-up, independent of sex, age, and hypertension (β 0.36, p = 0.006) while no association with current PASI was found. In conclusion, cardiac OD was less prevalent in psoriasis patients on infliximab treatment than controls. Hypertension was the major covariable for subclinical cardiac OD in psoriasis.

Download Full-text